Jan Egbert de Vries
Chairman at Artax, Inc.
Jan Egbert de Vries active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Artax, Inc. | Chairman | - | - |
Career history of Jan Egbert de Vries
Former positions of Jan Egbert de Vries
| Companies | Position | Start | End |
|---|---|---|---|
Tr1x, Inc.
 Tr1x, Inc. Miscellaneous Commercial ServicesCommercial Services Tr1x, Inc. is an American biotechnology company. The company was founded by Jan Egbert de Vries. Jan Egbert de Vries has been the CEO since incorporation. | Chief Executive Officer | - | 16/01/2024 |
| Founder | - | 16/01/2024 | |
AIMM Therapeutics BV
 AIMM Therapeutics BV Pharmaceuticals: MajorHealth Technology AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands. | Chief Executive Officer | 31/12/2009 | 30/12/2017 |
| Chairman | 31/12/2017 | 30/11/2020 | |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 31/12/2007 | 31/12/2009 |
| NOVARTIS AG | Corporate Officer/Principal | 31/12/1995 | 31/12/2008 |
| DNAX Research, Inc. | Corporate Officer/Principal | 31/12/1988 | 31/12/1996 |
Schering-Plough Research Institute
 Schering-Plough Research Institute Medical SpecialtiesHealth Technology Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ. | Director/Board Member | 31/12/1984 | 31/12/1987 |
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh
 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh Investment Trusts/Mutual FundsMiscellaneous Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek is a scientific research institute and a specialist clinic. The firm’s areas of research are including fundamental, clinical and translational cancer research. The company was founded in 1916 and is headquartered in Amsterdam, Netherlands. | Corporate Officer/Principal | 01/01/1969 | 31/12/1984 |
| CASSIOPEA S.P.A. | Director/Board Member | 31/03/2021 | - |
| Chairman | 30/04/2015 | 31/03/2021 | |
| Independent Dir/Board Member | 30/04/2015 | - |
Training of Jan Egbert de Vries
| University of Amsterdam | Doctorate Degree |
| University of Utrecht | Graduate Degree |
Statistics
International
| United States | 6 |
| Netherlands | 5 |
| Italy | 2 |
Operational
| Corporate Officer/Principal | 4 |
| Chairman | 3 |
| Director/Board Member | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| NOVARTIS AG | Health Technology |
| Private companies | 8 |
|---|---|
Cassiopea SpA
 Cassiopea SpA Pharmaceuticals: MajorHealth Technology Cassiopea SpA is a clinical-stage specialty pharmaceutical company. It engages in developing and commercializing medical dermatology products focusing on the topical treatment of acne, androgenic alopecia, and genital warts. The firm's products include Winlevi, Breezula, Clascoterone Solution, CB-06-02, and CB-06-01. The company was founded on July 30, 2013 and is headquartered in Milan, Italy. | Health Technology |
| Artax, Inc. | |
AIMM Therapeutics BV
AIMM Therapeutics BV Pharmaceuticals: MajorHealth Technology AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
| DNAX Research, Inc. | |
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh Investment Trusts/Mutual FundsMiscellaneous Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek is a scientific research institute and a specialist clinic. The firm’s areas of research are including fundamental, clinical and translational cancer research. The company was founded in 1916 and is headquartered in Amsterdam, Netherlands. | Miscellaneous |
Tr1x, Inc.
Tr1x, Inc. Miscellaneous Commercial ServicesCommercial Services Tr1x, Inc. is an American biotechnology company. The company was founded by Jan Egbert de Vries. Jan Egbert de Vries has been the CEO since incorporation. | Commercial Services |
Schering-Plough Research Institute
Schering-Plough Research Institute Medical SpecialtiesHealth Technology Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ. | Health Technology |
- Stock Market
- Insiders
- Jan Egbert de Vries
- Experience
